Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial

American Journal of Kidney Diseases

Volumn 69, Issue 3, 2017, Pages 389-399

  Rivara, Matthew B ^a,b   Yeung, Catherine K ^a,c   Robinson Cohen, Cassianne ^a,b   Phillips, Brian R ^c   Ruzinski, John ^a   Rock, Denise ^a   Linke, Lori ^a   Shen, Danny D ^c   Ikizler, T Alp ^d   Himmelfarb, Jonathan ^a,b  

^a Kidney Research Institute   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antioxidant; biomarker; cardiac function; cardiovascular risk; coenzyme Q10 (CoQ10); dietary supplement; end stage renal disease (ESRD); hemodialysis; Oxidative stress; predialysis blood pressure; randomized controlled trial

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ISOPROSTANE DERIVATIVE; TROPONIN T; UBIDECARENONE; BIOLOGICAL MARKER; UBIQUINONE;

ABDOMINAL PAIN; ADULT; AGE; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HEMODIALYSIS PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HEART; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; HEART; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PILOT PROJECTS; RENAL DIALYSIS; UBIQUINONE;

EID: 85008395835     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.08.041     Document Type: Article

References (41)

1. 1 Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 66:1 suppl 1 (2015), S1–S305.
2. 2 Longenecker, J.C., Coresh, J., Powe, N.R., et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13:7 (2002), 1918–1927.
3. 3 Cheung, A.K., Sarnak, M.J., Yan, G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:1 (2000), 353–362.
4. 4 Himmelfarb, J., Stenvinkel, P., Ikizler, T.A., Hakim, R.M., The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:5 (2002), 1524–1538.
5. 5 Stenvinkel, P., Diczfalusy, U., Lindholm, B., Heimbürger, O., Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 19:4 (2004), 972–976.
6. 6 Himmelfarb, J., McMenamin, M.E., Loseto, G., Heinecke, J.W., Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31:10 (2001), 1163–1169.
7. 7 Annuk, M., Zilmer, M., Lind, L., Linde, T., Fellström, B., Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:12 (2001), 2747–2752.
8. 8 Ikizler, T.A., Morrow, J.D., Roberts, L.J., et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58:3 (2002), 190–197.
9. 9 Rivara, M., Ikizler, T.A., Ellis, C., Mehrotra, R., Himmelfarb, J., Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients. BMC Nephrol, 16, 2015, 79.
10. 10 Fessel, J.P., Jackson Roberts, L., Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Antioxid Redox Signal 7:1-2 (2004), 202–209.
11. 11 Alkazemi, D., Egeland, G.M., Roberts, L.J., Kubow, S., Isoprostanes and isofurans as non-traditional risk factors for cardiovascular disease among Canadian Inuit. Free Radic Res 46:10 (2012), 1258–1266.
12. 12 Ramos, L.F., Shintani, A., Ikizler, T.A., Himmelfarb, J., Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol 19:3 (2008), 593–599.
13. 13 Mortensen, S.A., Rosenfeldt, F., Kumar, A., et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2:6 (2014), 641–649.
14. 10 supplementation on heart failure: a meta-analysis. Am J Clin Nutr 97:2 (2013), 268–275.
15. 15 Lim, S.C., Lekshminarayanan, R., Goh, S.K., et al. The effect of coenzyme Q10 on microcirculatory endothelial function of subjects with type 2 diabetes mellitus. Atherosclerosis 196:2 (2008), 966–969.
16. 16 Hamilton, S.J., Chew, G.T., Watts, G.F., Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 32:5 (2009), 810–812.
17. 17 Mehmetoglu, I., Yerlikaya, F.H., Kurban, S., Erdem, S.S., Tonbul, Z., Oxidative stress markers in hemodialysis and peritoneal dialysis patients, including coenzyme Q10 and ischemia-modified albumin. Int J Artif Organs 35:3 (2012), 226–232.
18. 18 Claessens, A.J., Yeung, C.K., Risler, L.J., Phillips, B.R., Himmelfarb, J., Shen, D.D., Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects. Ann Clin Biochem 53:pt 2 (2015), 265–273.
19. 19 Milne, G.L., Gao, B., Terry, E.S., Zackert, W.E., Sanchez, S.C., Measurement of F2- isoprostanes and isofurans using gas chromatography–mass spectrometry. Free Radic Biol Med 59 (2013), 36–44.
20. 20 Morrow, J.D., Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25:2 (2005), 279–286.
21. 21 White, I.R., Royston, P., Wood, A.M., Multiple imputation using chained equations: issues and guidance for practice. Stat Med 30:4 (2011), 377–399.
22. 22 Rubin, D.B., Multiple Imputation for Nonresponse in Surveys. 2004, Wiley-Interscience, Hoboken, NJ.
23. 23 Little, R.J., D'Agostino, R., Cohen, M.L., et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 367:14 (2012), 1355–1360.
24. 24 Hopke, P.K., Liu, C., Rubin, D.B., Multiple imputation for multivariate data with missing and below-threshold measurements: time-series concentrations of pollutants in the Arctic. Biometrics 57:1 (2001), 22–33.
25. 25 Madmani, M.E., Yusuf Solaiman, A., Tamr Agha, K., et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev, 6, 2014, CD008684.
26. 26 Young, J.M., Florkowski, C.M., Molyneux, S.L., et al. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens 25:2 (2012), 261–270.
27. 27 Ferrante, K.L., Shefner, J., Zhang, H., et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65:11 (2005), 1834–1836.
28. 28 Hyson, H.C., Kieburtz, K., Shoulson, I., et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord Off J Mov Disord Soc 25:12 (2010), 1924–1928.
29. 29 Macunluoglu, B., Kaya, Y., Atakan, A., et al. Serum coenzyme Q10 levels are associated with coronary flow reserve in hemodialysis patients. Hemodial Int 17:3 (2013), 339–345.
30. 30 Yeung, C.K., Billings, F.T., Claessens, A.J., et al. Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress. BMC Nephrol, 16, 2015, 183.
31. 31 Granata, S., Zaza, G., Simone, S., et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 10:1 (2009), 1–13.
32. 32 Yazdi, P.G., Moradi, H., Yang, J.-Y., Wang, P.H., Vaziri, N.D., Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. Int J Clin Exp Med 6:7 (2013), 532–539.
33. 33 Eckardt, K.-U., Bernhardt, W.W., Weidemann, A., et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl 99 (2005), S46–S51.
34. 34 Sluimer, J.C., Gasc, J.-M., van Wanroij, J.L., et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 51:13 (2008), 1258–1265.
35. 35 Onur, S., Niklowitz, P., Jacobs, G., Lieb, W., Menke, T., Döring, F., Association between serum level of ubiquinol and NT-proBNP, a marker for chronic heart failure, in healthy elderly subjects. Biofactors 41:1 (2015), 35–43.
36. 36 Alehagen, U., Johansson, P., Björnstedt, M., Rosén, A., Dahlström, U., Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 167:5 (2013), 1860–1866.
37. 37 Shults, C.W., Oakes, D., Kieburtz, K., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:10 (2002), 1541–1550.
38. 38 The Parkinson Study Group QE3 Investigators. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71:5 (2014), 543–552.
39. 39 Morrow, J.D., The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32:3-4 (2000), 377–385.
40. 40 Kadiiska, M.B., Gladen, B.C., Baird, D.D., et al. Biomarkers of Oxidative Stress Study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Radic Biol Med 38:6 (2005), 698–710.
41. 41 Montuschi, P., Barnes, P., Roberts, L.J., Insights into oxidative stress: the isoprostanes. Curr Med Chem 14:6 (2007), 703–717.